Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction

Vaccine

Volumn 30, Issue 4, 2012, Pages 737-744

  Den Brok, Martijn H ^a   Nierkens, Stefan ^a   Wagenaars, Jori A ^a   Ruers, Theo J ^b   Schrier, Carla C ^c   Rijke, Eric O ^c   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c INTERVET INTERNATIONAL BV   (Netherlands)

Author keywords

Adjuvants; Antigen presentation; Cancer; Cryo ablation; Dendritic cell; Immunotherapy; ISCOMs; Saponin; Vaccination

Indexed keywords

CANCER ANTIBODY; CPG 1668; GLYCOPROTEIN P 15095; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CRYOABLATION; DENDRITIC CELL; IMMUNE RESPONSE; IN VIVO STUDY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ABLATION; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CRYOSURGERY; DENDRITIC CELLS; MICE; MICE, INBRED C57BL; NEOPLASMS; SAPONINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84855351989     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.080     Document Type: Article

References (39)

1. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82(October (5)):497-505.
2. Harandi A.M., Medaglini D., Shattock R.J. Vaccine adjuvants: a priority for vaccine research. Vaccine 2010, 28(March (12)):2363-2366.
3. Wickelgren I. Immunology Mouse studies question importance of toll-like receptors to vaccines. Science 2006, 314(December (5807)):1859-1860.
4. Figdor C.G., de V.I., Lesterhuis W.J., Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10(May (5)):475-480.
5. Sun H.X., Xie Y., Ye Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27(July (33)):4388-4401.
6. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308(March (5958)):457-460.
7. Drane D., Gittleson C., Boyle J., Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007, 6(October (5)):761-772.
8. Maraskovsky E., Schnurr M., Wilson N.S., Robson N.C., Boyle J., Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009, 87(July (5)):371-376.
9. Nicholaou T., Ebert L.M., Davis I.D., McArthur G.A., Jackson H., Dimopoulos N., et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009, 15(March (6)):2166-2173.
10. den Brok M.H., Sutmuller R.P., van der Voort R., Bennink E.J., Figdor C.G., Ruers T.J., et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004, 64(June (11)):4024-4029.
11. den Brok M.H., Sutmuller R.P., Nierkens S., Bennink E.J., Frielink C., Toonen L.W., et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006, 95(October (7)):896-905.
12. Goldszmid R.S., Idoyaga J., Bravo A.I., Steinman R., Mordoh J., Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 2003, 171(December (11)):5940-5947.
13. Mulier S., Ni Y., Jamart J., Michel L., Marchal G., Ruers T. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Ann Surg Oncol 2008, 15(January (1)):144-157.
14. Apetoh L., Ghiringhelli F., Zitvogel L. Calreticulin dictates the immunogenicity of anti-cancer chemotherapy and radiotherapy. Med Sci (Paris) 2007, 23(March (3)):257-258.
15. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13(September (9)):1050-1059.
16. Sanchez-Ortiz R.F., Tannir N., Ahrar K., Wood C.G. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?. J Urol 2003, 170(July (1)):178-179.
17. Jansen T., Hofmans M.P., Theelen M.J., Manders F., Schijns V.E. Structure- and oil type-based efficacy of emulsion adjuvants. Vaccine 2006, 24(June (26)):5400-5405.
18. Ott G., Radhakrishnan R., Fang J.H., Hora M. The adjuvant MF59: a 10-year perspective. Vaccine adjuvants: preparation methods and research protocols 2000, 211-228. Humana Press Inc., Totowa, NJ. D.T. O'Hagan (Ed.).
19. Rijke E.O., Cornelius L., Schrier C. Experiences with a Tocopherol-based adjuvant in chickens. Advances in avian immunology research 1994, 265-271. Carfax Publishing Ltd., Oxfordshire, UK. T.F. Davison, N. Bumstead, P. Kaiser (Eds.).
20. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy. Cancer Res 2008, 68(July (13)):5390-5396.
21. Karttunen J., Sanderson S., Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 1992, 89(July (13)):6020-6024.
22. Nierkens S., den Brok M.H., Roelofsen T., Wagenaars J.A.L., Figdor C.G., Ruers T.J., et al. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS ONE 2009, 4(12):e8368.
23. den Brok M.H., Sutmuller R.P., Nierkens S., Bennink E.J., Toonen L.W., Figdor C.G.
24. Maraskovsky E., Sjolander S., Drane D.P., Schnurr M., Le T.T., Mateo L., et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 2004, 10(April (8)):2879-2890.
25. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21(February (1)):23-29.
26. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(June (7198)):1122-1126.
27. Kool M., Petrilli V., de Smedt T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181(September (6)):3755-3759.
28. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009, 106(January (3)):870-875.
29. Demana P.H., Davies N.M., Vosgerau U., Rades T. Pseudo-ternary phase diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by the lipid-film hydration method. Int J Pharm 2004, 270(February (1-2)):229-239.
30. Ronnberg B., Fekadu M., Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 1995, 13(October (14)):1375-1382.
31. Ronnberg B., Fekadu M., Behboudi S., Kenne L., Morein B. Effects of carbohydrate modification of Quillaja saponaria Molina QH-B fraction on adjuvant activity, cholesterol-binding capacity and toxicity. Vaccine 1997, 15(December (17-18)):1820-1826.
32. Schnurr M., Chen Q., Shin A., Chen W., Toy T., Jenderek C., et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005, 105(March (6)):2465-2472.
33. Schnurr M., Orban M., Robson N.C., Shin A., Braley H., Airey D., et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol 2009, 182(February (3)):1253-1259.
34. Duewell P., Kisser U., Heckelsmiller K., Hoves S., Stoitzner P., Koernig S., et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 2011, 187(July (1)):55-63.
35. Wilson N.S., Yang B., Morelli A.B., Koernig S., Yang A., Loeser S., et al. ISCOMATRIX vaccines mediate CD8(+) T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 2011, (September).
36. Machi J., Bueno R.S., Wong L.L. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg 2005, 29(November (11)):1364-1373.
37. Sabel M.S., Nehs M.A., Su G., Lowler K.P., Ferrara J.L., Chang A.E. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 2005, 90(March (1)):97-104.
38. Widenmeyer M., Shebzukhov Y., Haen S.P., Schmidt D., Clasen S., Boss A., et al. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer 2011, 128(June (11)):2653-2662.
39. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(August (8)):711-723.